🇺🇸

US SEC Filing Intelligence

· daily

US Executive Compensation Proxy SEC Filings — March 02, 2026

Crane Harbor Acquisition Corp. (CHAC), the sole filing in this Executive Compensation Insights stream, details a high-materiality (9/10) SPAC business combination with Xanadu Quantum Technologies Inc. via NewCo, with neutral sentiment and no disclosed prior period financial performance, metrics, or executive compensation specifics. The DEFM14A proxy seeks shareholder approval at an extraordinary general meeting on March 19, 2026, for the merger under a November 3, 2025 agreement, including a continuance from Cayman Islands to Ontario and massive share issuances (515M Class A Multiple Voting Shares, 79M Class B Subordinate Voting Shares). PIPE financing at $10.00 per share from Crane Harbor Sponsor affiliates underscores sponsor commitment amid no YoY/QoQ trends available. This positions CHAC for entry into quantum technologies, a high-growth sector, but highlights typical SPAC risks like dilution and approval dependency. No insider trading, capital allocation details (e.g., dividends/buybacks), or forward-looking financial guidance beyond transaction timelines are enriched, limiting period comparisons but flagging the March 19 catalyst as pivotal for market implications. Overall, the filing signals concentrated event-driven opportunity in quantum computing via SPAC de-SPACing.

1 high priority 1 total filings
· daily

US Executive Officer Management Changes SEC — March 02, 2026

Across 53 SEC filings on US executive and director changes from March 2, 2026 (covering events Feb-Mar 2026), the dominant theme is a surge in leadership transitions with 28 appointments/promotions (e.g., experienced CFOs/CEOs in Eaton, Asana, L3Harris) signaling continuity and growth conviction, contrasted by 19 resignations/retirements (e.g., planned in Civista, chaotic in BiomX/TON Strategy) and 6 restructurings/comp changes. Period-over-period trends show robust revenue growth in reporting firms: MongoDB Q4 FY2026 +27% YoY to $695.1M, Atlas +29% YoY; Dave Inc Q4 2025 +62% YoY to $163.7M, FY +60% YoY; Great Elm Q4 NII +50% QoQ to $0.31/share, though NAV -20% QoQ. Positive sentiment in 14/53 filings (tech/finance hires), negative/mixed in 9 (biotech distress), neutral dominant. Portfolio-level patterns: Banking sector orderly CEO successions (Civista, First Bancorp), tech internal promotions amid strong growth (Asana CFO, MongoDB CCO), biotech high turnover risks. Market implications: Bullish for stable transitions with growth backdrops (e.g., Eaton $27.4B 2025 rev), bearish for governance disputes (TON Strategy CEO firing with self-dealing claims); alpha in pre-IPO catalysts (L3Harris Missile Solutions) and buyback hikes (Dave $300M authorization).

53 high priority 53 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — March 02, 2026

Across 49 filings in the USA Corporate Distress & Bankruptcy stream, a bifurcated landscape emerges: 7 companies (14%) face acute delisting risks or compliance issues (e.g., Allurion, Graphjet, Iterum), while 70% involve proactive capital raises, debt refinancings, or M&A to extend runways amid distress signals, with no broad YoY revenue declines but frequent mentions of prior weak equity/market cap metrics. Biotech/pharma dominates (20+ filings) with mixed M&A outcomes like Pulmatrix termination but Gyre-Cullgen pivot, alongside heavy equity/debt issuances (e.g., $250M Zymeworks royalty note, $1.5B Targa notes) signaling liquidity preservation over growth. Forward-looking catalysts cluster in Q2 2026 (merger closes, approvals), with capital allocation tilting to debt exchanges/raises vs buybacks/dividends, reflecting strained balance sheets. Portfolio-level trends show 12/49 positive financings extending runway >2028 (e.g., Zymeworks beyond 2028), but 5 mixed restructurings introduce dilution risks. Implications: Short small-cap distress names pre-delisting, long M&A targets at premiums (AES 40.3%), monitor Q2 catalysts for turnarounds.

49 high priority 49 total filings
· daily

US SEC Trading Suspension Halt Orders — March 02, 2026

Across six US-listed small-cap companies in the Trading Suspensions stream (period March 2, 2026), regulatory pressures dominate with Nasdaq and NYSE delisting risks centered on bid price deficiencies, low stockholders' equity/market cap, and MVLS shortfalls; HCW Biologics (HCWB) is the sole positive outlier, regaining full Nasdaq Capital Market compliance on February 26, 2026, enabling capital access for immunotherapies. Graphjet Technology and Iterum Therapeutics face affirmed delistings with trading suspensions (Nov 13, 2025, and March 5, 2026, respectively), signaling severe distress and potential wind-downs. Mixed outcomes for Allurion Technologies (NYSE appeal post-FDA approval Feb 20, 2026, debt-to-equity swap), Northann Corp (compliance plan accepted to June 8, 2027), and My Size (180-day bid price cure to Aug 31, 2026). No uniform period-over-period financial trends evident due to regulatory focus, but forward-looking compliance extensions provide temporary trading continuity for 4/6 firms. Biotech/healthcare firms (3/6) show heightened vulnerability, with capital raises/debt restructurings as common countermeasures. Portfolio implication: Avoid delisted names; monitor appeals for short-term trading pops.

6 high priority 6 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 02, 2026

Across 49 SEC filings on USA Board Room Changes from March 2, 2026, the dominant theme is proactive board and C-suite refreshments, with 25+ new appointments/promotions of experienced executives (e.g., finance vets to banking/tech boards) outpacing 15+ resignations/retirements, often planned and amicable, signaling strong governance and strategic pivots amid growth pressures. Period-over-period trends show outliers like Dave Inc. Q4 2025 revenue +62% YoY and MongoDB +27% YoY with FCF +672% to $176.7M, contrasting Great Elm's NII +50% QoQ but NAV -20% QoQ to $8.07/share; aggregate, 3/5 financial reporters exhibited revenue acceleration averaging +47% YoY. Forward-looking catalysts include Dave's FY2026 revenue guide +25-28% to $690-710M, MongoDB FY2027 non-GAAP op income $545-565M, and enCore's Verdera share distribution post-resale registration. Capital allocation leans shareholder-friendly with Dave raising buybacks to $300M (+140%), Great Elm $0.30/share Q1 dividend (19.2% yield), but risks emerge in biotech distress (BioAtla 70% workforce cut). Banking sector orderly CEO successions (Civista, First Bancorp) highlight continuity; tech/biotech churn mixed but net positive. Portfolio implication: Favor leadership upgrades in growth sectors, monitor biotech turnarounds.

49 high priority 49 total filings
· daily

US Merger & Acquisition SEC Filings — March 02, 2026

A surge in US M&A and takeover activity dominates the 29 filings from March 2, 2026, with 12 completed mergers/acquisitions (primarily banking consolidations adding $20B+ in combined assets) and robust SPAC developments including 4 IPOs raising $800M+, 3 extensions, and 2 business combination approvals/proxies. Banking sector leads with 7 deals (e.g., HBT Financial +$1.8B assets, Farmers National +42% to $7.4B), driving footprint expansions in Midwest/East Coast without reported declines. Positive sentiment prevails in 17/29 filings (avg materiality 8.7/10), bolstered by accretive deals (e.g., Malibu Boats 7.2x EBITDA, Crexendo to $100M run-rate), though mixed signals in energy (Kosmos Q4 loss $377M despite +4% QoQ production). SPACs show high activity but delays/extensions flag execution risks. Forward-looking catalysts cluster in Q1 2026 (closings, earnings), with no insider trading disclosed but board additions signaling integration confidence. Portfolio trend: Asset growth avg +30% in banks vs sector contraction risks elsewhere; implications favor M&A arbitrage and regional bank longs amid consolidation wave.

29 high priority 29 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 02, 2026

Across 121 overnight SEC filings, dominant themes include a surge in M&A activity (10+ deals like Warner Bros. Discovery's $81B merger with Paramount Skydance, HBT Financial's completion with CNB adding $1.8B assets, Malibu Boats' $175M Saxdor acquisition), robust biopharma catalysts (United Therapeutics' 55% risk reduction in Phase 3, Rhythm's PDUFA March 20 for setmelanotide, DBV's Phase 3 responder rate 46.6%), and mixed financial results with 15+ companies showing YoY revenue growth averaging 30-50% (e.g., Venture Global +177%, RadNet +14.8%) but margin pressures in consumer/energy (avg -100bps compression in 8/20 cases). Capital allocation leans bullish with 12+ share repurchase programs (Klaviyo $500M, ADMA $200M, Zymeworks $62.5M used), dividend hikes (PROG +7.7%), and debt reductions (Bandwidth repurchased $100M notes). Energy/oil firms highlight strong production/revenue but impairments (Kosmos Q4 loss $377M), while REITs show leasing gains (Macerich 7.1M sq ft). Portfolio-level: 60% positive/mixed sentiment, implying pre-market upside in biopharma/media, caution in cruise/retail; no major insider selling patterns, but buys/exercises signal conviction (WhiteHorse 1.1M shares $8M, Ramaco CEO options). Forward catalysts cluster in H1-H2 2026 (NDAs, earnings, closings).

41 high priority 80 medium 121 total filings
· daily

New Federal Contractors — March 01, 2026

A single massive $20.65B cost-plus award fee contract for Lockheed Martin Services to manage DOE's Y-12 plant through 2027 dominates this period, signaling exceptional long-term revenue stability in government-owned facilities operations. Zero outlays despite the 43-year history highlight execution risks amid DOE budget dependence. Investors should prioritize Lockheed Martin for defense-industrial exposure while monitoring funding triggers.

1 total filings
· daily

Contract Deobligations Alert — March 01, 2026

A single massive $20.65B long-term DOE contract for Lockheed Martin Services underscores exceptional revenue visibility through 2027 in Y-12 nuclear facilities management, signaling bullish stability for Lockheed Martin Corp amid full and open competition. Zero outlays to date highlight execution risks but minimal obligation gaps suggest fully funded potential. Investors should prioritize monitoring DOE budgets for reimbursements and follow-on opportunities in GOCO operations.

1 total filings
· daily

Contract Option Exercises — March 01, 2026

Lockheed Martin Services secures a $20.65B cost-plus award fee contract with DOE for Y-12 plant management through Feb 2027, signaling strong revenue visibility in government-owned contractor-operated (GOCO) facilities. Despite zero outlays to date, the fully funded structure and full competition award highlight stability in facilities support services. Investors should monitor DOE budgets for execution risks amid this outsized single-contract concentration.

1 total filings
· daily

All DOE Contracts — March 01, 2026

A single $20.65B DOE contract for Lockheed Martin underscores exceptional long-term revenue stability in Y-12 plant management through 2027, providing high-confidence bullish signal for the company amid full and open competition. No outlays despite 43-year history flags execution risks tied to DOE budgets, warranting caution on near-term cash flows. Fully funded structure and follow-on potential position Lockheed as a prime watch item in facilities support services.

1 total filings
· daily

High-Value Federal Grants ($5M+) — March 01, 2026

A single massive $20.65B cost-plus contract awarded to Lockheed Martin Services, LLC for Y-12 plant management through Feb 2027 signals strong revenue visibility in DOE facilities operations. Despite zero outlays to date, the fully funded structure and full/open competition award underscore long-term stability for Lockheed Martin in NAICS 561210 services. Investors should monitor DOE budget execution amid funding risks, with potential follow-on opportunities post-2027.

1 total filings
· daily

DOE Energy Grants — March 01, 2026

A single massive $20.65B DOE contract awarded to Lockheed Martin Services underscores long-term revenue stability for Y-12 plant management through Feb 2027, signaling bullish commitment to GOCO facilities operations amid full competition. No outlays despite 2026 period highlight execution risks tied to DOE budgeting. Investors should prioritize Lockheed Martin for defense/energy services exposure with potential follow-on beyond 2027.

1 total filings
· daily

NME Blockbuster Approvals — February 28, 2026

FDA approval of LOARGYS (PEGZILARGINASE-NBLN) on Feb 23, 2026, delivers a bullish catalyst for Immedica Pharma AB via original NME with Priority Review and Orphan Drug status, enabling premium pricing and exclusivity. This isolated event in the NME Blockbuster stream signals strong regulatory momentum but lacks indication details for market sizing. Investors should prioritize monitoring commercial launch for revenue potential amid unknown competition.

1 total filings
· daily

Biotech Small-Cap Approvals — February 28, 2026

This one-day period saw 12 neutral generic ANDA approvals out of 13 records, concentrated in Brivaracetam (4 sponsors), Liraglutide (2), and Sitagliptin Phosphate (2), signaling broad generic portfolio expansions for small-cap sponsors but routine pricing pressure ahead. The sole bullish outlier is Immedica Pharma AB's priority-reviewed NME Orphan Drug BLA for LOARGYS (PEGZILARGINASE-NBLN), offering premium positioning via exclusivity. Investors should prioritize Immedica for growth while monitoring generic erosion in epilepsy and diabetes segments.

13 total filings
· daily

Orphan Drug Approvals — February 28, 2026

Immedica Pharma AB's FDA approval of LOARGYS (PEGZILARGINASE-NBLN) via priority review for an original NME orphan drug represents the period's sole bullish catalyst, enabling near-term commercial launch with exclusivity and premium pricing. Two identical neutral signals for Array Biopharma's Encorafenib highlight data redundancy and lack of material developments, signaling portfolio stability but no upside. Overall, sparse activity underscores selective orphan drug opportunities amid neutral biotech backdrop.

3 total filings